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Abstract With an increasing demand for efficacious, safe,
and affordable vaccines for human and animal use, process
intensification in cell culture-based viral vaccine production
demands advanced process strategies to overcome the limita-
tions of conventional batch cultivations. However, the use of
fed-batch, perfusion, or continuous modes to drive processes
at high cell density (HCD) and overextended operating times
has so far been little explored in large-scale viral vaccine
manufacturing. Also, possible reductions in cell-specific virus
yields for HCD cultivations have been reported frequently.
Taking into account that vaccine production is one of the most
heavily regulated industries in the pharmaceutical sector with
tough margins to meet, it is understandable that process inten-
sification is being considered by both academia and industry
as a next step toward more efficient viral vaccine production
processes only recently. Compared to conventional batch pro-
cesses, fed-batch and perfusion strategies could result in ten to
a hundred times higher product yields. Both cultivation strat-
egies can be implemented to achieve cell concentrations ex-
ceeding 107 cells/mL or even 108 cells/mL, while keeping low
levels of metabolites that potentially inhibit cell growth and
virus replication. The trend towards HCD processes is sup-
ported by development of GMP-compliant cultivation plat-
forms, i.e., acoustic settlers, hollow fiber bioreactors, and hol-
low fiber-based perfusion systems including tangential flow
filtration (TFF) or alternating tangential flow (ATF) technolo-
gies. In this review, these process modes are discussed in
detail and compared with conventional batch processes based
on productivity indicators such as space-time yield, cell con-
centration, and product titers. In addition, options for the pro-
duction of viral vaccines in continuous multi-stage bioreactors
such as two- and three-stage systems are addressed. While
such systems have shown similar virus titers compared to
batch cultivations, keeping high yields for extended produc-
tion times is still a challenge. Overall, we demonstrate that
process intensification of cell culture-based viral vaccine pro-
duction can be realized by the consequent application of fed-
batch, perfusion, and continuous systems with a significant
increase in productivity. The potential for even further im-
provements is high, considering recent developments in estab-
lishment of new (designer) cell lines, better characterization of
host cell metabolism, advances in media design, and the use of
mathematical models as a tool for process optimization and
control.
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Introduction
Most biologicals produced in animal cell culture are continu-
ously synthesized during the cell proliferation phase.
Recombinant proteins, for example, are typically produced
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in batch or fed-batch mode, where the product is accumulated
in the culture broth and harvested once peak concentrations
are reached (Castilho et al. 2008). In contrast, the production
of viral vaccines typically requires a cell growth phase follow-
ed by a virus replication phase (both typically operated in
batch mode) as most viruses propagate in a complex process
that requires the internalization of their genetic material into
the host cell, the synthesis of viral RNA/DNA and viral pro-
teins as well as the release of progeny virus particles (Aunins
2003). Furthermore, it has to be taken into account that the
replication process of lytic viruses results in cell death due to
apoptosis followed by cell degradation and release of contam-
inants such as cellular DNA and host cell proteins.
To increase virus production yields through process opti-
mization, three key factors need to be considered:
& Cell concentration and metabolic/physiological status of
the cells at time of infection (toi): As a general rule, cell
concentration defines final virus titers. However, it is es-
sential to perform infections on healthy cells, with no lim-
itation of key nutrients, not inhibited by accumulated by-
products such as lactate and ammonia, and in an appropri-
ate growth status (i.e., dividing/non-dividing, cell cycle
phase) (Demarchi and Kaplan 1977).
& Ratio of infectious particles to viable cells, namely multi-
plicity of infection (moi) at the time of infection (toi):
Since virus transport to the target cell in the culture medi-
um is governed by diffusion, an optimal amount of virus
particles per cell should be inoculated to counteract
degradation/inactivation of infectious virions before they
reach their host cell (Aunins 2003). In addition, for most
viruses, a too high number of virus particles per cell at toi
can promote replication of so-called defective interfering
particles (DIPs), which decreases maximum virus yields.
This is of particular importance in continuous cultivations
using cascades of stirred tank bioreactors (STR), where
decreases in virus titers for long cultivation times have
been observed as a consequence of DIP accumulation
(Frensing 2015; van Lier et al. 1990).
& Residence time (RT) of virus particles within the bioreac-
tor and time point of harvest (toh): The RT can be defined
as the time that a cell or a virus particle remains inside the
bioreactor and is characteristic for the cultivation mode. In
closed systems operated in batch cultivation mode, the RT
is identical for all particles and equivalent to the harvest
time. After having achieved maximum titers, virus infec-
tivity as well as the total number of virus particles can
decrease again (Aunins 2003), while the extracellular
DNA and protein contamination level can increase signif-
icantly due to cell lysis. Accordingly, time of harvest has
to be determined carefully, taking into account vaccine
type (live attenuated, inactivated) and downstream pro-
cessing requirements. In particular, for viral vaccines,
where potency depends totally or partially on infectivity
(e.g., live attenuated vaccines, viral vectors), a short RT/
early toh is beneficial. When batch knowledge is trans-
ferred to continuous systems, the picture is more complex
as not all particles spend the same time inside the contin-
uously operated bioreactor. In continuous bioreactors, an
important concept is the RT distribution, which is essen-
tially a statistical approach to describe the probability of
particles to leave the bioreactor (Levenspiel 1972; Sarkar
et al. 2015). Nevertheless, a good approximation is given
by the average RT that, in continuous STRs, equals the
inverse of the dilution rate (RT = 1/D).
In order to address the impact of the first key factor (cell
concentration, physiological status) on process intensification,
approaches towards optimization of upstream processes for
manufacturing of other biologicals, i.e., CHO cell-derived re-
combinant proteins, can serve as a general guideline. Here,
high cell density (HCD) processes have been developed for
the production of biopharmaceuticals over more than 20 years
(Kompala and Ozturk 2006; Ozturk 1994, 1996), and a high
number of products have been introduced into the market
(Kompala and Ozturk 2006; Pollock et al. 2013). Typically,
HCD processes rely on fed-batch or perfusion strategies and
the use of one or the other depends on specific requirements of
the product and technical aspects. However, perfusion biore-
actors have the potential to achieve higher cell concentrations
since they offer a constant nutrient-enriched environment
avoiding the accumulation of unwanted by-products
(Fig. 1a) (Castilho et al. 2008). In addition, these cultivation
conditions allow the use of cultivation systems with a low
footprint and with high volumetric production rates (Ozturk
1994, 1996). For process intensification in viral vaccine pro-
duction, however, significant differences compared to the
classical production process of recombinant proteins exist.
Due to the separation of most of the virus production process-
es in a cell growth phase and a virus replication phase, differ-
ent production profiles and kinetics are to be expected
(Fig. 1b). In particular, the use of specific process strategies
during virus propagation needs to be considered.
Regarding the cell retention in perfusion systems, a large
variety of examples can be found for the production of recom-
binant proteins (Pollock et al. 2013). In general, filtration-
based systems (i.e., internal and external spin filter, ATF and
TFF), gravity settlers, and acoustic filters have been extensive-
ly used in the industry as well as in academia (Clincke et al.
2013; Kompala and Ozturk 2006; Pollock et al. 2013). Some
of these systems have potential drawbacks such as filter clog-
ging (membrane-based systems) and limited scalability (grav-
ity settlers and acoustic filters). Accordingly, alternating tan-
gential flow (ATF) and tangential flow filtration (TFF) sys-
tems have attracted considerable attention since they have a
reduced risk of filter clogging (due to the cross-flow filtration)
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and can be easily scaled up based on the surface area of the
hollow fiber cartridge (Kompala and Ozturk 2006). All this
allows cultivations to very high cell concentrations in the or-
der of 108 cells/mL (Clincke et al. 2013). Other options for
HCD cultivation of animal cells are fixed-bed reactors and
entrapping retention systems. These systems, however, are
known for heterogeneities regarding the distribution of medi-
um components and gases (de la Broise et al. 1992) as well as
for their operational complexity (Kompala and Ozturk 2006).
Nevertheless, a recently developed fixed-bed bioreactor
(CellTank®, PerfuseCell) has shown homogeneous concentra-
tion of metabolites allowing cultivation of CHO K1 cells at
concentrations up to 2 × 108 cells/mL (Zhang et al. 2015).
Process yields of viral vaccine manufacturing can also be
improved using true continuous systems, i.e., chemostats
(Kilburn and van Wezel 1970) or multi-stage systems such
as the two-stage bioreactor (Frensing et al. 2013).
Continuous bioreactors can operate at steady-state conditions
(constant cell and metabolite concentration, pH value, and
osmolality) avoiding shutdown times for cleaning and sterili-
zation cycles typical for batch operation (Hoskisson and
Hobbs 2005; Konstantinov and Cooney 2015). It was estimat-
ed that continuous cultivations can reduce operational costs by
up to 55 % compared to batch processes (Walther et al. 2015).
Manufacturing of biologicals at steady-state conditions is also
assumed to positively influence the quality of the final product
as, e.g., more consistent glycoform profiles and reduced pro-
tein deamidation can be obtained (Konstantinov and Cooney
2015). If viral vaccines are produced, steady-state operation at
optimum virus RT could help to prevent fast degradation of
infectious virus particles compared to batch cultivations, be-
ing beneficial for production of live-attenuated vaccines or
viral vectors such asMVAvirus (Jordan et al. 2013). The main
problem with the use of true continuous cultivation strategies
in viral vaccine production is, however, that it is not clear
whether vaccines produced would be acceptable for regulato-
ry agencies such as FDA and EMA as several open questions
remain to be answered regarding the long-term genetic
stability of cell substrates and virus strains (Gallo-Ramirez
et al. 2015). In particular, it has to be investigated in detail,
whether undesired viral mutations can accumulate overpro-
duction time that can negatively influence potency and safety
of vaccines. Similarly, in continuous systems, moi can in-
crease during cultivation time as a consequence of virus rep-
lication and therefore promote excessive production of DIPs
as addressed above (Frensing 2015). Finally, there is still little
experience regarding more complex aspects of the viral life
cycle (i.e., virus latency, lytic stages) on virus yields and on
vaccine quality (Kilburn and vanWezel 1970; Roumillat et al.
1980).
In the following, we present a comprehensive overview of
options for process intensification in cell culture-based viral
vaccine production. In particular, we consider the establish-
ment of HCD cultivations and the use of continuous multi-
stage bioreactors. The focus of HCD will be on fed-batch
strategies and operation in perfusion mode using ATF sys-
tems, hollow fiber bioreactors and acoustic filters as these
systems have the highest potential for production of viral vac-
cines. In addition, process options regarding the use of two-
and three-stage continuous bioreactors for virus production
are addressed. Literature regarding baculovirus-insect cell ex-
pression systems is highlighted here due to its significant con-
tribution to the understanding of virus dynamics in continuous
cultures. As very few studies deal with HCD cultivations or
continuous production systems in large-scale virus vaccine
manufacturing, mainly, results obtained at laboratory scale
will be presented for illustration of process options.
Virus production at high cell densities
The term Bhigh cell density^ was previously defined as any
cell concentration in the order of 107 cells/mL (Griffiths et al.
1992). However, authors have often taken as a reference the
typical cell concentrations achieved so far for a reference pro-
duction process (typically batch) for that specific cell line. For
many of the conventional cell lines used in vaccine produc-
tion, this was in the range of 2 × 106 cells/mL to 4 × 106 cells/
mL. Based on that, cell concentrations one order of magnitude
higher than those obtained by established cultivation process-
es have been considered as high cell densities.
Given the nature of most virus propagation processes,
where cells are infected at the late exponential growth phase,
the cell concentrations need first to be increased to concentra-
tions that cannot be achieved in batch mode for a HCD pro-
cess. In addition, virus propagation at such high cell concen-
trations must be performed at the optimal conditions to avoid
the so-called cell density effect, which is a reduction in the
cell-specific virus yield (Lindsay and Betenbaugh 1992;
Maranga et al. 2003). A summary of HCD virus production
processes and their main characteristics is given in Table 1.
Fig. 1 Schematic representation of the perfusion-based high cell density
(HCD) production of recombinant proteins and viruses. a Concentration
profiles of different performance parameters in a perfused bioreactor for
the production of recombinant proteins. b Concentration profiles of
different performance parameters in a perfused bioreactor for the
production of viruses. V volume, XV cell concentration, P recombinant
protein concentration, Vir virus particle concentration, S substrate
(glucose) concentration
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Process options to achieve high densities for adherent
and suspension cells
It is important to note that maximum cell concentrations that
are typically achieved differ between adherent and suspension
cells. Provided similar aeration conditions, the maximum
number of adherent cells that can be obtained in bioreactors
depends on the available growth surface, while the maximal
growth of suspension cells is mainly limited by the total
amount of nutrients in the growth medium and the accumula-
tion of growth-inhibiting compounds. In addition, further lim-
itations for HCD processes using suspension cells such as
space, reactor design, and operation as well as aeration have
to be considered as discussed previously (Ozturk 1996). In
particular, the addition of medium (fed-batch) or the exchange
of medium (perfusion) is usually not sufficient for obtaining
HCD with adherent cells, and an increase in growth surface,
for example, by the addition of microcarriers in STRs, is re-
quired. The use of microcarriers offers the additional advan-
tage that it allows an easy exchange of medium by sedimen-
tation of carriers after switching off the stirrer of cultivation
vessels or stopping the rocking unit of wave systems. For
instance, an increase from 1.8 × 106 cells/mL to 1.1 × 107
cells/mL could be achieved for adherent Madin-Darby canine
kidney (MDCK) cells when increasing the concentration of
the microcarrier Cytodex 1 from 2.0 to 12.5 g/L using a re-
peated fed-batch process (Bock et al. 2011). Medium ex-
change was performed based on an estimated cell-specific
feeding rate (Dowd et al. 2003). In another example, the pro-
liferation of bovine kidney (BK) cells on Cytodex 3 for the
propagation of Parapoxvirus ovis up to 7.0 × 106 cells/mL
was carried out using a periodic medium exchange
(Pohlscheidt et al. 2008) based on the minimum glucose con-
centration measured. Finally, a recirculation-based feeding
mode was applied for the propagation of Vero cells grown
on microcarriers at about 6.0 × 106 cells/mL for subsequent
infection with various poliovirus serotypes (Thomassen et al.
2014). In this process, a fresh medium of an STR was circu-
lated through the cultivation bioreactor at increasing rates de-
pending on cultivation time.
Although similar to the recirculation strategy followed by
Thomassen et al. (2014), a special case has been reported for
the proliferation of both adherent and suspensionMDCK cells
in a single-used hollow fiber bioreactor for propagation of
pandemic influenza virus (Tapia et al. 2014). Here, cell con-
centrations of about 3.0 × 107 cells/mL were obtained by
recirculation of fresh medium through the hollow fibers pro-
viding nutrients to the cells and diluting accumulated toxic
compounds.
Besides adherent cell lines, suspension cells are routinely
grown to HCD using fed-batch (Xie and Wang 1994) and
perfusion-based feeding strategies (Kompala and Ozturk
2006). For example, the use of perfusion systems in the
production of adenoviral vectors has been described by
Nadeau and Kamen (2003). However, cell concentrations did
not exceed 6.0 × 106 cells/mL and neither a significant change
in volumetric yield nor in cell-specific yields was observed
compared to batch cultivations. Since this application has been
comprehensively described by Nadeau and Kamen (2003), it
will not be addressed further in this review. More recently,
external cell retention systems such as acoustic filters (Petiot
et al. 2011) or the ATF system (Genzel et al. 2014) have been
used in various vaccine production processes established in
research laboratories. Using an acoustic filter, suspension
HEK293 cells have been grown to concentrations approaching
6.0 × 106 cells/mL before infection with a recombinant adeno-
virus type 5 (Henry et al. 2005) and type A influenza virus
(Petiot et al. 2011), respectively. In this case, cell growth con-
tinued even after infection reaching 11 (Henry et al. 2005) and
14 × 106 cells/mL (Petiot et al. 2011). In another study, the
designer cell lines AGE1.CR and CAP have been cultivated
to 4.8 and 3.3 × 107 cells/mL, respectively, for the propagation
of type A influenza virus (Genzel et al. 2014; Villiger-Oberbek
et al. 2015) using an ATF system. Significant efforts have also
been reported regarding options to intensify vaccine production
processes using PER.C6 cells. Although this cell line can be
cultivated up to 1.0 × 107 cells/mL in batch (Sanders et al.
2013) and above 1.0 × 108 cells/mL in perfusion mode using
an ATF system (Mercier et al. 2014; Vellinga et al. 2014),
current production of adenoviral vectors (serotype 26 and 35)
are carried out only at a PER.C6 cell concentration of about
1.6 × 107 cells/mL (Van and Luitjens 2011).
The theoretical maximum cell concentration, which can be
obtained for animal cells, is considered to be about 109 cells/
mL (Ozturk 1996). Given that the supply of cells with critical
substrates and the removal of growth-inhibiting compounds
can always be guaranteed by appropriate feeding and perfu-
sion strategies, the maximum cell concentration largely de-
pends on the volumetric oxygen transfer coefficient (kLa) that
the cultivation system supports. Accordingly, depending on
the cell line, the use of conventional stirred tank or wave
bioreactors with kLa values up to 55 1/h should allow achiev-
ing cell densities in the order of 1 × 108 cells/mL. As expected,
experiments show that it is challenging to obtain such high
concentration in these cultivation systems and that additional
issues, such as accumulation of CO2 to toxic concentrations,
have to be taken into account. For example, Clincke et al.
(2013) have reported previously on CHO cell cultivations ex-
ceeding 2 × 108 cells/mL, where a suitable aeration/agitation
strategy combined with CO2-stripping needed to be
implemented.
Process options to maintain high cell-specific virus yields
To achieve high virus titers, cells should typically be infected
during the late exponential growth phase. In addition, an
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optimal supply of nutrients at toi is required (Aunins 2003).
The latter can be achieved by a complete medium exchange
prior to addition of the virus seed (Bock et al. 2011;
Pohlscheidt et al. 2008) or by an intensive medium renewal
during the cell proliferation phase (Thomassen et al. 2014).
The use of a perfusion rate of two reactor volumes per day
starting immediately after virus infection also helped to im-
prove adenovirus yields in HEK293 cells (Henry et al. 2004).
Here, losses of infectious virus particles in the clarified frac-
tion at the early phase of infection were compensated by in-
fecting with an moi two times higher (moi = 20) than in the
reference process in batch (moi = 10).
In order to support virus propagation after virus addition,
fed-batch mode and/or discontinuous medium exchange have
been carried out, especially in processes based on
immobilized cells. For example, infectingMCDK cells grown
on Cytodex 1, Bock et al. (2011) demonstrated that
performing a repeated fed-batch process during the first 2 to
10 h post infection allowed to obtain cell-specific influenza A
virus yields threefolds higher compared to a conventional
batch process. Similarly, Pohlscheidt et al. (2008) applied a
so-called volume-expanded fed-batch strategy during propa-
gation of a P. ovis strain in BK cells grown on Cytodex 3. This
cultivation strategy consisted in the discontinuous addition of
medium to a final volume four times larger than the initial
operation volume. Here, total virus yield was increased 40-
fold, while virus titers and volumetric productivity were in-
creased in one and two orders of magnitude, respectively, in
comparison to a batch process (Pohlscheidt et al. 2008).
Compared to a typical fed-batch process (with shorter volume
additions), the volume-expanded fed-batch strategy resulted
in an almost sixfold increase in total virus yield. Finally, daily
harvesting of virus-containing supernatants in a hollow fiber
systemwas reported to produce high titers of influenza Avirus
and cell-specific virus yields comparable to those obtained in
the typical batch production mode in STR (Tapia et al. 2014).
This shows that this strategy can be suitable not only for the
production of viruses that propagate exclusively in mitotic
cells and have a long replication cycle, such as the mink en-
teritis virus (MEV) (Roya andMehrad 2008), but also for fast-
propagating strains, e.g., influenza A virus.
When operating processes with suspension cell lines, con-
tinuous virus harvest/medium exchange is more feasible. In
this regard, acoustic filters have been used for cell retention
and harvesting of a cell-free virus broth. For example, influ-
enza A virus produced in HEK293 cells was continuously
harvested in the clarified supernatant with cell-specific yields
of about 4000 virions per cell (Genzel et al. 2014; Petiot et al.
2011). Here, to avoid virus loss in the clarified fraction, me-
dium exchange was not carried out for some hours after infec-
tion to allow for an efficient uptake of virions into cells. As
addressed before, other commercially available separation
systems used at industrial scale, e.g., gravity settlers or spin
filters (Pollock et al. 2013), could also allow for continuous
virus harvests when infecting suspension cells at concentra-
tions about 2 × 107 cells/mL (Kompala and Ozturk 2006).
Furthermore, continuous virus harvests at cell concentrations
in the order of 108 could be also possible using new types of
bioreactors such as the perfusion bioreactor CellTank®.
An alternative approach to perform virus propagation using
perfusion systems is the retention of both cells and virus par-
ticles within the bioreactor. For the case of the ATF system
mentioned before, it was shown that continuous medium ex-
change resulted in high cell-specific yields of influenza A
virus at laboratory scale. However, the choice of a suitable
hollow fiber membrane seems to be a crucial factor since the
pore size of membranes seems to have an influence on pro-
ductivity (Genzel et al. 2014). It is evident that when using
membrane-based separation systems, a sound characterization
of cell retention during the growth phase must be carried out
since any change in porosity and average pore size will have a
negative impact on virus retention or harvest titers. Whether it
is beneficial to continuously harvest virus particles or to retain
them within the bioreactor during the whole virus production
phase has to be determined in advance and characteristics of
filtration modules have to be chosen accordingly. It might be
even beneficial to consider the use of different pore sizes for
both cell growth and virus production phases. Similar to
acoustic filter-based processes (Genzel et al. 2014; Petiot
et al. 2011), for ATF-based processes, a medium exchange
should be avoided for few hours after addition of virus seeds
to allow for an efficient uptake of virions into cells.
Although ATF and TFF systems share a similar separation
principle, i.e., tangential flow filtration, TFF systems have not
been used for virus production, so far. One possible reason
might be the fact that cells are being exposed to a larger shear
stress as TFF systems involve the use of peristaltic pumps
(Nienow et al. 2013). It can be expected, however, that im-
provements such as the implementation of low-stress
pumping systems, e.g., magnetic levitated pumps, will pro-
mote the use of TFF systems.
Advantages and challenges of current HCD production
processes
Most of the recent approaches toward HCD cultivations in
vaccine production have demonstrated that it is possible to
maintain or even increase cell-specific virus yields. Given an
accumulation of contaminating DNA and host cell proteins
proportional to the concentration of cells, the impact on fol-
lowing downstream operations should not be adversely affect-
ed. In contrast, the concentration of clarified harvests that is
typically performed prior to subsequent chromatography steps
either needs only minor modification or, in the best-case sce-
nario, is not required anymore. Furthermore, the use of perfu-
sion systems and a continuous medium exchange during virus
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propagation phase can mitigate the accumulation of DNA and
host cell proteins in the viral harvests. Accordingly, regarding
the establishment of HCD cultivations, a negative impact on
final product quality is not anticipated.
Nevertheless, there are still various productivity indicators
and economic aspects that must be considered, before estab-
lishing industrial-scale applications. For example, based on
the volumetric productivity (the total amount of virus particles
produced per volume of culture medium consumed, virus par-
ticles/L), the so-called space time yield (STY, virus particles/
(L h)) can be determined taking into account the complete
production time. This performance indicator better reflects
overall process costs than mere volumetric (virus particles/L)
or cell-specific yields (virus particles/cell). This way, even
processes with very high product concentration and high
cell-specific yield compared to a batch process could be less
productive given the large volumes of media consumed or the
extended production time or both (Genzel et al. 2014). Also,
production process parameters at HCD could impact intrinsic
properties, such as the glycosylation of viral proteins and the
ratio of infectious virions to the total number of virions, which
are key properties of both viral vaccines and viral vectors.
Accordingly, small-scale studies addressing medium optimi-
zation for HCD cultivations, the establishment of medium
feeding, cell cultivation and virus harvesting strategies, and
the analysis of critical quality attributes of products are essen-
tial to promote the use of HCD processes in routine viral
vaccine production.
Multi-stage bioreactors for continuous virus
production
The establishment of continuous cultures can be tracked back
to the 1950s (Novick and Szilard 1950), where it raised many
questions and challenges in the production of biologicals.
Finally, however, the focus was on the establishment of batch
cultivations due to their advantages regarding ease of opera-
tion and process robustness. In addition, productivity in-
creased significantly, as fast advances in genetic engineering
were made (Hoskisson and Hobbs 2005). With an ever in-
creasing number of biologicals introduced into the market,
however, the interest in more efficient manufacturing plat-
forms is back and tackling several challenges for the next
decades, such as the integration of upstream and downstream
in fully continuous operated processes, will take a greater role
(Warikoo et al. 2012). Continuous production has several
well-known advantages compared to the batch cultures, such
as steady-state operation, high volumetric efficiency, and low-
er plant turndown that enhance process yield. Continuous pro-
duction of many biologicals has been achieved with the use of
STR operated in single (chemostat) or multi-stage STR con-
figurations. The use of chemostats (Novick and Szilard 1950)
is suitable for molecular biology research or for simple cases,
where cells are cultivated on a defined substrate, to obtain
maximum biomass and/or high product yields (Málek and
Fenel 1966). Nevertheless, stable operation with chemostats
can fail, when the product is produced in small amounts
(Fencl et al. 1972), when cell growth is inhibited by the prod-
uct, or in case cell deteriorates as occuring, e.g., with lytic
viruses. An alternative to chemostats is multi-stage systems,
such as several STRs in series, or STRs in series with tubular
bioreactors (Hu and Bentley 2007; Málek and Fencl 1966).
One interesting approach for virus production is the use of
two-stage STR bioreactors, as depicted in Fig. 2a. Here, the
first reactor serves only for cell propagation and the subse-
quent bioreactor for virus infection and continuous virus rep-
lication (Frensing et al. 2013). The addition of more STR in
series (Fig. 2b) could potentially increase virus yields by ap-
proaching the residence time distribution of a plug-flow reac-
tor or by increasing the RT of cells in the system, with virus
release in the subsequent vessels (Gori 1965; van Lier et al.
1990). Therefore, in the following section, the use of multi-
stage STR systems using cascades of two and three STR is
addressed as an option for process intensification in viral vac-
cine production.
Fig. 2 Schematic representations of continuous multi-stage stirred tank
reactor (STR) setups. a Scheme of a continuous two-stage STR system
used for continuous influenza A virus production described by Frensing
et al. (2013); b a multi-stage STR setup following a plug-flow-like
configuration (Hu et al. 1997; Málek and Fencl 1966; van Lier et al.
1990), in which a cascade of STR was used. As before, the first
bioreactor (n = 1) is exclusively for cell propagation, while virus is
produced in the subsequent vessels
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Overview of two- and three-stage bioreactors used
for continuous production of viruses
Multi-stage systems have been used for propagation of bacte-
riophages in bacteria (Jacobson and Jacobson 1966) as well as
for replication of viruses in human cells (Gori 1965), insect
cells (Kompier et al. 1988), and avian cells (Frensing et al.
2013) (see Table 2). Additional options for continuous viral
vaccine production exist for processes using persistently in-
fected cells, as reported for instance (Roumillat et al. 1980;
Roumillat et al. 1979) for herpes simplex virus growth in
lymphoblastoids. Eventually, semi-continuous virus produc-
tion is also possible in cultures using adherent cells or in
cultivation systems involving hollow fiber units. Shen et al.
(1996), for instance, used multiple harvest strategies for retro-
viral production in a NIH 3T3 fibroblast-derived adherent
amphotropic murine cell line (pMFG/ΨCRIP) for efficient
retroviral production. However, as these options involve only
one single stage, where the cell growth phase and the virus
replication phase are taking place in the same compartment,
they are not considered in this section. Accordingly, in
Table 2, only examples for continuous multi-stage production
systems established at laboratory scale are summarized.
Production of poliovirus and adenovirus
The term Blysostat^ was first used to describe a two-stage and
three-stage bioreactor for cultivation of poliovirus 1 and ade-
novirus replicated in a Hela S-3-1 and a Hela-derived KB cell
line, respectively (Gori 1965). Poliovirus type 1 was grown
with a yield of 421 TCID50 per cell and adenovirus type 14
with a yield of 116 TCID50 per cell. This pioneer work dem-
onstrated clearly that a continuous production of viruses is
possible and introduced a basic mathematical description of
two and three continuous STR bioreactors for virus produc-
tion. It also pointed out that special considerations have to be
taken into account for thermolabile viruses. In particular, virus
particles have to be removed from the STRwith a dilution rate
exceeding the specific virus inactivation rate. Furthermore, it
is important to keep infected cells in the bioreactor until lysed
(or until virus release ceases in case of non-lytic viruses).
However, with a life cycle of 5 to 24 h as found for many
viruses relevant in vaccine production, this might result in
non-optimal steady state conditions and require specific mea-
sures to keep virus yields at a high level. Finally, cell concen-
trations at steady state have to be selected carefully to avoid
substrate limitations or the accumulation of inhibiting by-
products of metabolism or viral compounds.
Production of baculovirus
A significant contribution using multi-stage bioreactors and
the baculovirus-insect cell expression system was done by
the group of Tramper and Vlak (Kompier et al. 1988). In a
first publication, two experiments using two-stage cultivation
systems operated for 25 and 60 days were described that
achieved steady-state production levels of polyhedra and
non-occluded virus (NOV) particles for up to 25 days. In this
work, for the first time, it was observed that a drop in virus
titers is possible at advanced production times (35 days) in
continuous mode. And it was suggested that this was due to
a Bpassage effect^ induced by DIPs (Krell 1996). A first math-
ematical model that used a first-order reaction mechanismwas
introduced later (De Gooijer et al. 1989) to describe
baculovirus production in two- and three-stage cultivation
systems. The model predicted well the time courses of the
viable cell and the non-infected cell concentrations in the virus
production bioreactor, but did not describe the passage effect.
This last aspect was later covered with a structured model,
where the effect of DIPs on virus titers of two- and three-
stage STR bioreactors was considered explicitly (De Gooijer
et al. 1992). In another publication, a three-stage bioreactor
setup (using two vessels for infection) was compared against a
two-stage bioreactor system for baculovirus production (van
Lier et al. 1990). It was shown that the use of a three-stage
bioreactor accelerated the occurrence of viruses with a higher
virus passage number, which in turn resulted in an earlier drop
in virus yield (passage effect) compared to two-stage cultiva-
tions. Thus, three-stage bioreactor setups seem to be disadvan-
tageous for baculovirus production compared to two-stage
bioreactor systems as a more plug-flow-like configuration
seems to result in viruses with high passage number. In the
following, more studies (Lier et al. 1990; van Lier et al. 1992)
were carried out using a two-stage bioreactor system to pro-
duce a recombinant baculovirus containing the LacZ gene
expressingβ-galactosidase. For the first time, a DNA analysis
showed the existence of a predominant mutant baculovirus
that lacked about 40 % of the DNA genome, including the
LacZ gene. This confirmed the presence of DIPs in continuous
multi-stage baculovirus cultivations and their impact in pro-
cess productivity. In addition, it allowed to develop hypothe-
ses regarding possible mechanisms of DIP formation (Kool
et al. 1991). In another study, baculoviruses were genetically
engineered to maintain expression levels (van Lier et al.
1994). However, virus production still decreased after about
30 days of continuous operation. Finally, production in the
two-stage reactor systemwas optimized by performing repeat-
ed semi-continuous infections, in which an inoculum of the
previous infection was used as seed virus (van Lier et al.
1996). This mode of operation led to an enhancement in per-
formance, compared to continuously operated two-stage sys-
tems with regard to longer-term operation. In a more recent
study (Pijlman et al. 2004), stability of the virus was increased
by the utilization of extra homologous repeat regions, which
are located throughout the baculovirus genome and are be-
lieved to act as origins of viral DNA replication. This resulted
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in prolonged protein expression and improved the stability of
baculovirus expression vectors for the large-scale protein pro-
duction in insect-cell bioreactors.
Production of influenza virus
In a recent study carried out in our laboratory (Frensing et al.
2013), influenza virus A/PR/8/34 (RKI) was continuously
produced with the avian cell line AGE1.CR.pIX in a two-
stage bioreactor setup operated continuously for 18 days.
Virus titers similar to those of batch cultivations published
by Lohr et al. (2009) were observed. Unfortunately, virus titers
fluctuated over several orders of magnitude due to the pres-
ence of defective interfering particles (DIPs), which were con-
firmed by a PCR assay. A segregated mathematical model of
the two-stage system suggested that constant virus titers can
only be obtained in the absence of DIPs. Currently, different
approaches using the avian suspension cel l l ine
AGE1.CR.pIX (Lohr et al. 2014) as a substrate for virus rep-
lication are being evaluated in our laboratory to overcome this
hurdle for continuous production of influenza virus.
Outlook on high cell density cultivations
and continuous multi-stage bioreactors
It is clear that a long way is still to be passed in vaccine
manufacturing to reach the level of process intensification
established for other biologicals, i.e., the production of recom-
binant proteins in CHO cells. Nevertheless, results achieved at
the laboratory scale shed a very positive light regarding op-
tions for further optimization of large-scale viral vaccine pro-
duction. Combining knowledge obtained for process intensi-
fication in the production of other cell culture-derived biolog-
icals (i.e., the optimization of media, development of designer
cell lines, introduction of fed-batch/continuous perfusion sys-
tems), advances in automation technologies (on-line
monitoring/control of metabolites and cell concentration),
and availability of technologies for establishing HCD under
cGMP conditions (i.e., membrane-based perfusion systems
and hollow fiber units) should allow to catch up fast with
the increasing demands for potent and save vaccines at low
costs. Continuous processes using multi-stage stirred tank bio-
reactor systems are also an interesting option to batch produc-
tion of viruses. In particular, at laboratory scale, experiments
have demonstrated that harvests with similar virus titers can be
obtained, e.g., for influenza virus production. Duration of con-
tinuous processes, however, is clearly limited by the accumu-
lation of DIPs in the population of many (if not most) DNA
and RNA viruses. Unfortunately, the presence of DIPs can
significantly reduce product titers, and this effect seems to
stronger if the number of vessels in a cascade is increased.
Thus, the use of two-stage stirred tank bioreactor systems
seems to be the best option for intensification of viral vaccine
production processes. Furthermore, multi-stage STR systems
involving the use of three or more STRs in series would prob-
ably not be accepted in large-scale vaccine manufacturing due
to the complexity of operation and the increasing risk of pro-
cess failure. Furthermore, it has to be considered for both two-
stage and multi-stage STRs that there is a higher risk of accu-
mulating unwanted antigenic variations of virus strains due to
extended process times. Accordingly, all steps towards pro-
cess intensification have to be carefully evaluated with respect
to their potential impact on the quality of the final product, i.e.,
safety and immunogenicity. Nevertheless, the implementation
of HCD cultivations using fed-batch or perfusion strategies
seems currently a very attractive option for process intensifi-
cation. HCD cultivations have the potential to achieve cell
concentrations exceeding 108 cells/mL, and it has been shown
by several research groups that the so-called cell density effect
can be overcome for many viruses. Accordingly, it should be
possible to improve productivity in vaccine manufacturing 10-
to 100-fold compared to conventional batch cultivations.
While it may take several years to translate these ideas into
large-scale vaccine manufacturing, HCD cultivations, and for
some viruses, cascades of continuous stirred tank bioreactors,
are the most promising steps toward manufacturing of more
efficacious, safe, and cost-effective viral vaccines.
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